vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Urban Edge Properties (UE). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $132.6M, roughly 1.3× Urban Edge Properties). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 12.2%). Over the past eight quarters, Urban Edge Properties's revenue compounded faster (11.6% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.
ESPR vs UE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $132.6M |
| Net Profit | — | $22.6M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 17.1% |
| Revenue YoY | 143.7% | 12.2% |
| Net Profit YoY | — | -6.7% |
| EPS (diluted) | $0.32 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $132.6M | ||
| Q4 25 | $168.4M | $119.6M | ||
| Q3 25 | $87.3M | $120.1M | ||
| Q2 25 | $82.4M | $114.1M | ||
| Q1 25 | $65.0M | $118.2M | ||
| Q4 24 | $69.1M | $116.4M | ||
| Q3 24 | $51.6M | $112.4M | ||
| Q2 24 | $73.8M | $106.5M |
| Q1 26 | — | $22.6M | ||
| Q4 25 | — | $12.4M | ||
| Q3 25 | $-31.3M | $14.9M | ||
| Q2 25 | $-12.7M | $58.0M | ||
| Q1 25 | $-40.5M | $8.2M | ||
| Q4 24 | — | $30.1M | ||
| Q3 24 | $-29.5M | $9.1M | ||
| Q2 24 | $-61.9M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 11.3% | ||
| Q3 25 | -11.4% | 13.4% | ||
| Q2 25 | 8.6% | 53.9% | ||
| Q1 25 | -34.0% | 7.6% | ||
| Q4 24 | -6.4% | 27.6% | ||
| Q3 24 | -31.0% | 8.9% | ||
| Q2 24 | 3.5% | 30.6% |
| Q1 26 | — | 17.1% | ||
| Q4 25 | — | 10.4% | ||
| Q3 25 | -35.9% | 12.4% | ||
| Q2 25 | -15.4% | 50.8% | ||
| Q1 25 | -62.2% | 6.9% | ||
| Q4 24 | — | 25.9% | ||
| Q3 24 | -57.2% | 8.1% | ||
| Q2 24 | -83.9% | 28.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $0.32 | $0.09 | ||
| Q3 25 | $-0.16 | $0.12 | ||
| Q2 25 | $-0.06 | $0.46 | ||
| Q1 25 | $-0.21 | $0.07 | ||
| Q4 24 | $-0.14 | $0.25 | ||
| Q3 24 | $-0.15 | $0.07 | ||
| Q2 24 | $-0.33 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $50.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.4B |
| Total Assets | $465.9M | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | $167.9M | $48.9M | ||
| Q3 25 | $92.4M | $77.8M | ||
| Q2 25 | $86.1M | $53.0M | ||
| Q1 25 | $114.6M | $48.0M | ||
| Q4 24 | $144.8M | $41.4M | ||
| Q3 24 | $144.7M | $67.9M | ||
| Q2 24 | $189.3M | $78.6M |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $-302.0M | $1.4B | ||
| Q3 25 | $-451.4M | $1.4B | ||
| Q2 25 | $-433.5M | $1.4B | ||
| Q1 25 | $-426.2M | $1.4B | ||
| Q4 24 | $-388.7M | $1.4B | ||
| Q3 24 | $-370.2M | $1.3B | ||
| Q2 24 | $-344.2M | $1.3B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $465.9M | $3.3B | ||
| Q3 25 | $364.0M | $3.3B | ||
| Q2 25 | $347.1M | $3.3B | ||
| Q1 25 | $324.0M | $3.3B | ||
| Q4 24 | $343.8M | $3.3B | ||
| Q3 24 | $314.1M | $3.2B | ||
| Q2 24 | $352.3M | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $39.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.1M | ||
| Q4 25 | $45.2M | $182.7M | ||
| Q3 25 | $-4.3M | $55.7M | ||
| Q2 25 | $-31.4M | $43.5M | ||
| Q1 25 | $-22.6M | $32.6M | ||
| Q4 24 | $-35.0M | $153.2M | ||
| Q3 24 | $-35.3M | $36.6M | ||
| Q2 24 | $-7.2M | $41.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $81.8M | ||
| Q3 25 | — | $26.1M | ||
| Q2 25 | — | $19.6M | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $42.5M | ||
| Q3 24 | $-35.5M | $12.2M | ||
| Q2 24 | $-7.3M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 68.4% | ||
| Q3 25 | — | 21.7% | ||
| Q2 25 | — | 17.2% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | 36.6% | ||
| Q3 24 | -68.7% | 10.8% | ||
| Q2 24 | -9.9% | 18.6% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 0.0% | 84.4% | ||
| Q3 25 | 0.0% | 24.6% | ||
| Q2 25 | 0.0% | 20.9% | ||
| Q1 25 | 0.0% | 17.5% | ||
| Q4 24 | 0.0% | 95.1% | ||
| Q3 24 | 0.3% | 21.7% | ||
| Q2 24 | 0.1% | 20.1% |
| Q1 26 | — | 1.73× | ||
| Q4 25 | — | 14.71× | ||
| Q3 25 | — | 3.73× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 3.97× | ||
| Q4 24 | — | 5.09× | ||
| Q3 24 | — | 4.03× | ||
| Q2 24 | — | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
UE
| Rental revenue | $124.2M | 94% |
| Other | $8.4M | 6% |
